Le Lézard
Classified in: Health
Subject: PDT

Takara Bio Announces Launch of Beta Cell Differentiation Service

MOUNTAIN VIEW, Calif., May 17, 2018 /PRNewswire/ -- The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis® Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.

Takara Bio, Inc., Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy.

The gold standard in this field involves the use of primary islets of Langerhans, which are difficult and costly to obtain. Islets containing insulin-secreting beta cells come from donors with different genetic backgrounds, confounding results by adding variability to cellular models and assays. The new differentiation service complements an existing suite of stem cell services and provides a reliable and plentiful source of mature beta cells from customer-specified hiPSCs, enabling beta cell functional studies, diabetes modeling, and compound screening for insulin secretion and regulation.

Catharina Brandsten, Director R&D at Takara Bio Europe AB, said, "Compared with human primary pancreatic islet beta cells, iPS-derived beta cells provide better access to cells and reduced batch-to-batch variability, providing reproducible and biologically relevant data. Our standardized method mimics embryonic development to manufacture large quantities of cryopreserved beta cells that secrete insulin and C-peptide, making the cells an excellent research tool for disease modeling and drug discovery."

About Takara Bio
The Takara Bio Group of companies is committed to improving the human condition through biotechnology. It is led by Takara Bio Inc. which represents the biomedical business interests of its parent company, Takara Holdings Inc. The Takara Bio companies support the life science market through the Takara, Clontech, and Cellartis brands, with the Cellartis brand focusing on stem cell-derived products and services for drug discovery, disease modeling, and applications within regenerative medicine. Learn more about Takara Bio at takara-bio.com (Japanese) and takarabio.com (English).


SOURCE Takara Bio Group

These press releases may also interest you

at 06:30
MAXIMUS , a leading provider of government services worldwide, announced today that it has signed a new contract with the North Carolina Department of Health and Human Services (DHHS) to provide Medicaid managed care enrollment broker services. This...

at 06:10
The global orthopedic devices market size is expected to reach USD 43.1 billion by 2024, according to a study by Grand View Research, Inc. It is anticipated to expand at a CAGR of 4.4% over the forecast period. Major market drivers include rising...

at 06:07
Whether treatment for opioid abuse and dependence most commonly emphasized methadone administration, naltrexone injection, group psychotherapy or another procedure in 2017 depended on the state or region where the patient received care, according to...

at 06:00
Project High Five (PH5), an online community designed to help keep kids engaged in team sports longer, today announced the official launch of its online platform. While 30 million kids play team sports every year, 70% of kids quit by age 13. With...

at 06:00
TMR foretells the global point-of-care diagnostics market to expand at a 6.9% CAGR during the forecast tenure 2016-2024 to be valued at an US$11.7 bn by 2024. The market bagged a US$6.8 bn in 2016. By application, infectious disease test could rank...

at 06:00
WellCare Health Plans, Inc. announced today that on August 13, 2018 it completed an offering of $750 million aggregate principal amount of 5.375% senior notes due 2026 (the "notes"). The notes were issued at 100.0% and bear interest at 5.375%....

News published on 17 may 2018 at 08:00 and distributed by: